Nicola Baldini

List of Publications by Year
in descending order

198 papers	10,529 citations	31902 53 h-index	40881 93 g-index
199 all docs	199 docs citations	199 times ranked	13772 citing authors

#	Article	IF	Citations
1	Impact of the acid microenvironment on bone cancers. , 2022, , 305-317.		0
2	Protocol of Co-Culture of Human Osteoblasts and Osteoclasts to Test Biomaterials for Bone Tissue Engineering. Methods and Protocols, 2022, 5, 8.	0.9	6
3	Validation of a Cleanroom Compliant Sonication-Based Decellularization Technique: A New Concept in Nerve Allograft Production. International Journal of Molecular Sciences, 2022, 23, 1530.	1.8	1
4	Assessment of Collagen-Based Nanostructured Biomimetic Systems with a Co-Culture of Human Bone-Derived Cells. Cells, 2022, 11, 26.	1.8	3
5	FT-IR Spectral Signature of Sensitive and Multidrug-Resistant Osteosarcoma Cell-Derived Extracellular Nanovesicles. Cells, 2022, 11, 778.	1.8	3
6	Ultrasound-guided injection of platelet-rich plasmaÂor cord blood platelet-rich plasma in nonunion: a randomized controlled trial. Regenerative Medicine, 2022, 17, 271-281.	0.8	2
7	Exploring Metabolic Adaptations to the Acidic Microenvironment of Osteosarcoma Cells Unveils Sphingosine 1-Phosphate as a Valuable Therapeutic Target. Cancers, 2021, 13, 311.	1.7	16
8	Osteonecrosis of the Femoral Head Safely Healed with Autologous, Expanded, Bone Marrow-Derived Mesenchymal Stromal Cells in a Multicentric Trial with Minimum 5 Years Follow-Up. Journal of Clinical Medicine, 2021, 10, 508.	1.0	19
9	Curcumin-Loaded Nanoparticles Impair the Pro-Tumor Activity of Acid-Stressed MSC in an In Vitro Model of Osteosarcoma. International Journal of Molecular Sciences, 2021, 22, 5760.	1.8	15
10	Acid-Induced Inflammatory Cytokines in Osteoblasts: A Guided Path to Osteolysis in Bone Metastasis. Frontiers in Cell and Developmental Biology, 2021, 9, 678532.	1.8	8
11	Acid Microenvironment in Bone Sarcomas. Cancers, 2021, 13, 3848.	1.7	15
12	Ionized jet deposition of antimicrobial and stem cell friendly silver-substituted tricalcium phosphate nanocoatings on titanium alloy. Bioactive Materials, 2021, 6, 2629-2642.	8.6	21
13	3D Printing and Bioprinting to Model Bone Cancer: The Role of Materials and Nanoscale Cues in Directing Cell Behavior. Cancers, 2021, 13, 4065.	1.7	18
14	Strawberry-Derived Exosome-Like Nanoparticles Prevent Oxidative Stress in Human Mesenchymal Stromal Cells. Biomolecules, 2021, 11, 87.	1.8	113
15	The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma. Cancers, 2021, 13, 5855.	1.7	14
16	Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 2020, 12, e11131.	3.3	154
17	The Microfluidic Trainer: Design, Fabrication and Validation of a Tool for Testing and Improving Manual Skills. Micromachines, 2020, 11, 872.	1.4	0
18	Unravelling the Effect of Citrate on the Features and Biocompatibility of Magnesium Phosphate-Based Bone Cements. ACS Biomaterials Science and Engineering, 2020, 6, 5538-5548.	2.6	7

#	Article	IF	Citations
19	Citrate Supplementation Restores the Impaired Mineralisation Resulting from the Acidic Microenvironment: An In Vitro Study. Nutrients, 2020, 12, 3779.	1.7	2
20	Nanodecoration of electrospun polymeric fibers with nanostructured silver coatings by ionized jet deposition for antibacterial tissues. Materials Science and Engineering C, 2020, 113, 110998.	3.8	28
21	The human tumor microbiome is composed of tumor typeâ€“specific intracellular bacteria. Science, 2020, 368, 973-980.	6.0	1,077
22	Benign albeit glycolytic: MCT4 expression and lactate release in giant cell tumour of bone. Bone, 2020, 134, 115302.	1.4	4
23	Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. Injury, 2020, 51, S63-S73.	0.7	32
24	Coâ€“culture systems of osteoblasts and osteoclasts: Simulating in vitro bone remodeling in regenerative approaches. Acta Biomaterialia, 2020, 108, 22-45.	4.1	103
25	Photodynamic Surgery for Feline Injection-Site Sarcoma. BioMed Research International, 2019, 2019, 1-9.	0.9	10
26	Osteoporosis-related variations of trabecular bone properties of proximal human humeral heads at different scale lengths. Journal of the Mechanical Behavior of Biomedical Materials, 2019, 100, 103373.	1.5	14
27	New Advances in the Study of Bone Tumors: A Lesson From the 3D Environment. Frontiers in Physiology, 2019, 10, 814.	1.3	43
28	Biomarkers of bone healing induced by a regenerative approach based on expanded bone marrowâ€“derived mesenchymal stromal cells. Cytotherapy, 2019, 21, 870-885.	0.3	9
29	Role of Citrate in Pathophysiology and Medical Management of Bone Diseases. Nutrients, 2019, 11, 2576.	1.7	55
30	Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis. Cancers, 2019, 11, 779.	1.7	25
31	Pre-clinical Models for Studying the Interaction Between Mesenchymal Stromal Cells and Cancer Cells and the Induction of Stemness. Frontiers in Oncology, 2019, 9, 305.	1.3	20
32	Effect of calcium phosphate heparinization on the in vitro inflammatory response and osteoclastogenesis of human blood precursor cells. Journal of Tissue Engineering and Regenerative Medicine, 2019, 13, 1217-1229.	1.3	4
33	Cause and effect of microenvironmental acidosis on bone metastases. Cancer and Metastasis Reviews, 2019, 38, 133-147.	2.7	28
34	Î±,Î³-Diketocarboxylic Acids and Their Esters Act as Carbonic Anhydrase IX and XII Selective Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 661-665.	1.3	18
35	The Emerging Roles of Extracellular Vesicles in Osteosarcoma. Frontiers in Oncology, 2019, 9, 1342.	1.3	33
36	Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer. Frontiers in Oncology, 2019, 9, 1332.	1.3	2

#	Article	IF	Citations
37	Auto-Allo Graft Parallel Juxtaposition for Improved Neuroregeneration in Peripheral Nerve Reconstruction Based on Acellular Nerve Allografts. Annals of Plastic Surgery, 2019, 83, 318-325.	0.5	7
38	Noncellular Modification of Acellular Nerve Allografts for Peripheral Nerve Reconstruction: A Systematic Critical Review of the Animal Literature. World Neurosurgery, 2019, 122, 692-703.e2.	0.7	12
39	The Effects of Systemic and Local Acidosis on Insulin Resistance and Signaling. International Journal of Molecular Sciences, 2019, 20, 126.	1.8	32
40	Cell-Enhanced Acellular Nerve Allografts for Peripheral Nerve Reconstruction: A Systematic Review and a Meta-Analysis of the Literature. Neurosurgery, 2019, 85, 575-604.	0.6	12
41	Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. Biomaterials, 2019, 196, 100-108.	5.7	87
42	Acid microenvironment promotes cell survival of human bone sarcoma through the activation of cIAP proteins and NF-Î°B pathway. American Journal of Cancer Research, 2019, 9, 1127-1144.	1.4	10
43	Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. Oncogenesis, 2018, 7, 20.	2.1	20
44	Spheroidâ€based 3D cell cultures identify salinomycin as a promising drug for the treatment of chondrosarcoma. Journal of Orthopaedic Research, 2018, 36, 2305-2312.	1.2	19
45	Biological effects of metal degradation in hip arthroplasties. Critical Reviews in Toxicology, 2018, 48, 170-193.	1.9	41
46	Validation of Suitable Housekeeping Genes for the Normalization of mRNA Expression for Studying Tumor Acidosis. International Journal of Molecular Sciences, 2018, 19, 2930.	1.8	18
47	Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism. Frontiers in Oncology, 2018, 8, 329.	1.3	3
48	Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients, 2018, 10, 1293.	1.7	15
49	A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol. Stem Cells International, 2018, 2018, 1-13.	1.2	25
50	Prominent role of RAB39A-RXRB axis in cancer development and stemness. Oncotarget, 2018, 9, 9852-9866.	0.8	19
51	Exosome-like Nanovesicles Isolated from Citrus limon L. Exert Antioxidative Effect. Current Pharmaceutical Biotechnology, 2018, 19, 877-885.	0.9	83
52	Clinical Trial of Radiotherapy After Intravenous Injection of Acridine Orange for Patients with Cancer. Anticancer Research, 2018, 38, 481-489.	0.5	15
53	Does chronic raise of metal ion levels induce oxidative <scp>DNA</scp> damage and hypoxiaâ€like response in patients with metalâ€onâ€metal hip resurfacing?. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2017, 105, 460-466.	1.6	7
54	Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression. Clinical Cancer Research, 2017, 23, 3721-3733.	3.2	150

#	Article	IF	Citations
55	Focus Ion Beam/Scanning Electron Microscopy Characterization of Osteoclastic Resorption of Calcium Phosphate Substrates. Tissue Engineering - Part C: Methods, 2017, 23, 118-124.	1.1	13
56	Therapeutic implications of tumor interstitial acidification. Seminars in Cancer Biology, 2017, 43, 119-133.	4.3	82
57	Orthoplastic surgical collaboration is required to optimise the treatment of severe limb injuries: A multi-centre, prospective cohort study. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2017, 70, 715-722.	0.5	70
58	Osteoclast differentiation from human blood precursors on biomimetic calcium-phosphate substrates. Acta Biomaterialia, 2017, 50, 102-113.	4.1	39
59	MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: A new rationale for the pathogenesis of osteolytic bone metastases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3254-3264.	1.8	47
60	Mesenchymal stroma: Role in osteosarcoma progression. Cancer Letters, 2017, 405, 90-99.	3.2	123
61	Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-ÎºB activation. International Journal of Cancer, 2017, 140, 1331-1345.	2.3	107
62	Treatment for long bone metastases based on a systematic literature review. European Journal of Orthopaedic Surgery and Traumatology, 2017, 27, 205-211.	0.6	98
63	Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Networks in Cancer. Frontiers in Pharmacology, 2017, 8, 411.	1.6	6
64	Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: Implication for the treatment of postmenopausal bone loss. PLoS ONE, 2017, 12, e0181230.	1.1	25
65	Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma. Oncotarget, 2017, 8, 54478-54496.	0.8	35
66	Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance. Oncotarget, 2016, 7, 63408-63423.	0.8	78
67	Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells International, 2016, 2016, 1-13.	1.2	164
68	Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion. PLoS ONE, 2016, 11, e0166500.	1.1	76
69	Multimodal transfer of MDR by exosomes in human osteosarcoma. International Journal of Oncology, 2016, 49, 189-196.	1.4	115
70	Metabolism and microenvironment in cancer plasticity. Cancer & Metabolism, 2016, 4, .	2.4	12
71	Energy metabolism in osteoclast formation and activity. International Journal of Biochemistry and Cell Biology, 2016, 79, 168-180.	1.2	147
72	The Role of Autophagy in the Maintenance of Stemness and Differentiation of Mesenchymal Stem Cells. Stem Cell Reviews and Reports, 2016, 12, 621-633.	5.6	91

#	Article	IF	Citations
73	New couplings, old problems: Is there a role for ceramicâ€onâ€metal hip arthroplasty?. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2016, 104, 204-209.	1.6	16
74	Effects of hypoxia on osteogenic differentiation of mesenchymal stromal cells used as a cell therapy for avascular necrosis of the femoral head. Cytotherapy, 2016, 18, 1087-1099.	0.3	38
75	Identification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells. PLoS ONE, 2016, 11, e0149481.	1.1	47
76	Cell-based Assay System for Predicting Bone Regeneration in Patient Affected by Aseptic Nonunion and Treated with Platelet Rich Fibrin. Current Pharmaceutical Biotechnology, 2016, 17, 1079-1088.	0.9	7
77	Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. American Journal of Cancer Research, 2016, 6, 859-75.	1.4	18
78	Prolonged Exposure to Hypoxic Milieu Improves the Osteogenic Potential of Adipose Derived Stem Cells. Journal of Cellular Biochemistry, 2015, 116, 1442-1453.	1.2	31
79	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget, 2015, 6, 7424-7437.	0.8	25
80	Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells. Journal of Medicinal Chemistry, 2015, 58, 4073-4079.	2.9	55
81	Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 1593-1605.	1.5	28
82	Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Research and Therapy, 2015, 6, 127.	2.4	599
83	Hypoxia enhances proliferation and stemness of human adipose-derived mesenchymal stem cells. Cytotechnology, 2015, 67, 1073-1084.	0.7	92
84	Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells. Current Pharmaceutical Design, 2015, 21, 4088-4094.	0.9	17
85	Impairment of Lysosomal Activity as a Therapeutic Modality Targeting Cancer Stem Cells of Embryonal Rhabdomyosarcoma Cell Line RD. PLoS ONE, 2014, 9, e110340.	1.1	43
86	How Do Metal Ion Levels Change over Time in Hip Resurfacing Patients? A Cohort Study. Scientific World Journal, The, 2014, 2014, 1-7.	0.8	9
87	Effect of acetabular cup design on metal ion release in two designs of metalâ€onâ€metal hip resurfacing. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2014, 102, 1595-1601.	1.6	2
88	Comparative â€œin vitroâ€•evaluation of the antiresorptive activity residing in four Ayurvedic medicinal plants. Hemidesmus indicus emerges for its potential in the treatment of bone loss diseases. Journal of Ethnopharmacology, 2014, 154, 462-470.	2.0	17
89	Organisational Change and the Institutionalisation of University Patenting Activity in Italy. Minerva, 2014, 52, 27-53.	1.4	35
90	V-ATPase as an effective therapeutic target for sarcomas. Experimental Cell Research, 2014, 320, 21-32.	1.2	47

#	Article	IF	Citations
91	Involvement of HIF-1Î± activation in the doxorubicin resistance of human osteosarcoma cells. Oncology Reports, 2014, 32, 389-394.	1.2	62
92	Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget, 2014, 5, 7575-7588.	0.8	121
93	V-ATPase as an effective therapeutic target for sarcomas. Experimental Cell Research, 2014, 320, 21-32.	1.2	28
94	MicroRNA expression profiling of human bone marrow mesenchymal stem cells during osteogenic differentiation reveals Osterix regulation by miR-31. Gene, 2013, 527, 321-331.	1.0	168
95	Do Ion Levels in Metal-on-metal Hip Resurfacing Differ From Those in Metal-on-metal THA at Long-term Followup?. Clinical Orthopaedics and Related Research, 2013, 471, 2964-2971.	0.7	20
96	Preparation method and growth factor content of platelet concentrate influence the osteogenic differentiation of bone marrow stromal cells. Cytotherapy, 2013, 15, 830-839.	0.3	58
97	Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patientsâ€™ bed. Journal of Translational Medicine, 2013, 11, 268.	1.8	115
98	Sustained Autocrine Induction and Impaired Negative Feedback of Osteoclastogenesis in CD14+ Cells of Giant Cell Tumor of Bone. American Journal of Pathology, 2013, 182, 1357-1366.	1.9	7
99	V-ATPase is a candidate therapeutic target for Ewing sarcoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1105-1116.	1.8	62
100	Serum levels of fibroblast growth factor 2 in children with orthopedic diseases: Potential role in predicting bone healing. Journal of Orthopaedic Research, 2013, 31, 249-256.	1.2	13
101	Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas. International Journal of Oncology, 2013, 43, 95-102.	1.4	40
102	Orthoplastics. Plastic and Reconstructive Surgery, 2013, 131, 313e-314e.	0.7	4
103	The Effect of Perineurotomy on Nerve Regeneration in Diabetic Rats. Plastic and Reconstructive Surgery, 2013, 131, 929e-930e.	0.7	0
104	New Trends Based on Experimental Results in the Treatment of Sarcoma. , 2013, , 37-48.		0
105	Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Frontiers in Physiology, 2012, 3, 359.	1.3	437
106	Enhancing Osteoconduction of PLLA-Based Nanocomposite Scaffolds for Bone Regeneration Using Different Biomimetic Signals to MSCs. International Journal of Molecular Sciences, 2012, 13, 2439-2458.	1.8	37
107	The Effect of Poly(<scp>d</scp> , <scp>l</scp> -Lactide-co-Glycolide)-Alendronate Conjugate Nanoparticles on Human Osteoclast Precursors. Journal of Biomaterials Science, Polymer Edition, 2012, 23, 1285-1300.	1.9	28
108	Translational Research of Photodynamic Therapy with Acridine Orange which Targets Cancer Acidity. Current Pharmaceutical Design, 2012, 18, 1414-1420.	0.9	31

#	Article	IF	Citations
109	The Combined Use of Mesenchymal Stromal Cells and Scaffolds for Bone Repair. Current Pharmaceutical Design, 2012, 18, 1796-1820.	0.9	59
110	A regenerative approach for bone repair in congenital pseudarthrosis of the tibia associated or not associated with type 1 neurofibromatosis: correlation between laboratory findings and clinical outcome. Cytotherapy, 2012, 14, 306-314.	0.3	22
111	Insulin receptor isoforms are differently expressed during human osteoblastogenesis. Differentiation, 2012, 83, 242-248.	1.0	28
112	Epineurotomy of the median nerve in carpal tunnel release: a systematic review and an attempt of metanalysis. European Orthopaedics and Traumatology, 2012, 3, 257-260.	0.1	2
113	The Transition Towards Entrepreneurial Universities: An Assessment of Academic Entrepreneurship in Italy. SSRN Electronic Journal, 2012, , .	0.4	3
114	The natural compound Alizarin as an osteotropic drug for the treatment of bone tumors. Journal of Orthopaedic Research, 2012, 30, 1486-1492.	1.2	49
115	University patenting: patterns of faculty motivations. Technology Analysis and Strategic Management, 2011, 23, 103-121.	2.0	29
116	Neuroblastoma and bone metastases: Clinical significance and prognostic value of Dickkopf 1 plasma levels. Bone, 2011, 48, 152-159.	1.4	26
117	Osteoblasts from a mandibuloacral dysplasia patient induce human blood precursors to differentiate into active osteoclasts. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 711-718.	1.8	27
118	Effects of Osteogenic Differentiation Inducers on in Vitro Expanded Adult Mesenchymal Stromal Cells. International Journal of Artificial Organs, 2011, 34, 998-1011.	0.7	29
119	In vitro models for the evaluation of angiogenic potential in bone engineering. Acta Pharmacologica Sinica, 2011, 32, 21-30.	2.8	29
120	IGF2 derived from SH-SY5Y neuroblastoma cells induces the osteoclastogenesis of human monocytic precursors. Experimental Cell Research, 2011, 317, 2147-2158.	1.2	11
121	Flexible polymeric ultrathin film for mesenchymal stem cell differentiation. Acta Biomaterialia, 2011, 7, 2883-2891.	4.1	28
122	Resorbable Glassâ€“Ceramic Phosphate-based Scaffolds for Bone Tissue Engineering: Synthesis, Properties, andIn vitroEffects on Human Marrow Stromal Cells. Journal of Biomaterials Applications, 2011, 26, 465-489.	1.2	34
123	Recent highlights on bone stem cells: a report from Bone Stem Cells 2009, and not onlyâ€¦. Journal of Cellular and Molecular Medicine, 2010, 14, 2614-2621.	1.6	6
124	Plateletâ€rich plasma impairs osteoclast generation from human precursors of peripheral blood. Journal of Orthopaedic Research, 2010, 28, 792-797.	1.2	35
125	Potential role of tartrateâ€resistant acid phosphatase 5b (TRACP 5b) as a surrogate marker of late loosening in patients with total hip arthroplasty: A cohort study. Journal of Orthopaedic Research, 2010, 28, 887-892.	1.2	14
126	Gene Expression Patterns Related to Osteogenic Differentiation of Bone Marrowâ€“Derived Mesenchymal Stem Cells DuringEx VivoExpansion. Tissue Engineering - Part C: Methods, 2010, 16, 511-524.	1.1	64

#	Article	IF	Citations
127	Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia. Bone, 2010, 46, 780-788.	1.4	23
128	Do royalties really foster university patenting activity? An answer from Italy. Technovation, 2010, 30, 109-116.	4.2	55
129	University spin-offs and their environment. Technology Analysis and Strategic Management, 2010, 22, 859-876.	2.0	32
130	Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma. Cancer Research, 2009, 69, 2443-2452.	0.4	96
131	Endothelial cells incubated with plateletâ€rich plasma express PDGFâ€B and ICAMâ€1 and induce bone marrow stromal cell migration. Journal of Orthopaedic Research, 2009, 27, 1493-1498.	1.2	34
132	Role of PLLA plasma surface modification in the interaction with human marrow stromal cells. Journal of Applied Polymer Science, 2009, 114, 3602-3611.	1.3	37
133	Osteogenic properties of late adherent subpopulations of human bone marrow stromal cells. Histochemistry and Cell Biology, 2009, 132, 547-557.	0.8	23
134	InÂvitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering. Journal of Materials Science: Materials in Medicine, 2009, 20, 45-50.	1.7	33
135	Implementing Bayhâ€“Dole-like laws: Faculty problems and their impact on university patenting activity. Research Policy, 2009, 38, 1217-1224.	3.3	66
136	A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGAâ€“ALE conjugate. Nanomedicine, 2009, 4, 161-175.	1.7	66
137	Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. International Journal of Oncology, 2009, 34, 1387-93.	1.4	11
138	Sensitivity to implant materials in patients with total knee arthroplasties. Biomaterials, 2008, 29, 1494-1500.	5.7	164
139	Polylactic acid fibre-reinforced polycaprolactone scaffolds for bone tissue engineering. Biomaterials, 2008, 29, 3662-3670.	5.7	184
140	Negative effects of university patenting: Myths and grounded evidence. Scientometrics, 2008, 75, 289-311.	1.6	49
141	Does Ion Release Differ Between Hip Resurfacing and Metal-on-metal THA?. Clinical Orthopaedics and Related Research, 2008, 466, 700-707.	0.7	54
142	Histogenetic Characterization of Giant Cell Tumor of Bone. Clinical Orthopaedics and Related Research, 2008, 466, 2081-2091.	0.7	52
143	Serum ion levels after ceramicâ€onâ€ceramic and metalâ€onâ€metal total hip arthroplasty: 8â€year minimum followâ€up. Journal of Orthopaedic Research, 2008, 26, 1569-1576.	1.2	40
144	Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. International Journal of Cancer, 2008, 123, 1526-1535.	2.3	20

#	Article	IF	Citations
145	Effects of prelamin A processing inhibitors on the differentiation and activity of human osteoclasts. Journal of Cellular Biochemistry, 2008, 105, 34-40.	1.2	21
146	Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials, 2008, 29, 1400-1411.	5.7	123
147	Increased osteoclast activity is associated with aggressiveness of osteosarcoma. International Journal of Oncology, 2008, 33, 1231-8.	1.4	39
148	Bioresorbable Phosphate Scaffolds for Bone Regeneration. Key Engineering Materials, 2007, 361-363, 241-244.	0.4	4
149	Expression of cell adhesion receptors in human osteoblasts cultured on biofunctionalized poly-(Îµ-caprolactone) surfaces. Biomaterials, 2007, 28, 3668-3678.	5.7	40
150	To patent or not to patent? A survey of Italian inventors on motivations, incentives, and obstacles to university patenting. Scientometrics, 2007, 70, 333-354.	1.6	154
151	University patenting and licensing activity: a review of the literature. Research Evaluation, 2006, 15, 197-207.	1.3	72
152	Institutional changes and the commercialization of academic knowledge: A study of Italian universitiesâ€™ patenting activities between 1965 and 2002. Research Policy, 2006, 35, 518-532.	3.3	163
153	The Act on inventions at public research institutions: Danish universities' patenting activity. Scientometrics, 2006, 69, 387-407.	1.6	26
154	Sensitivity to implant materials in patients undergoing total hip replacement. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2006, 77B, 257-264.	1.6	112
155	Plasma levels of receptor activator of nuclear factor-ÎºB ligand and osteoprotegerin in patients with neuroblastoma. International Journal of Cancer, 2006, 119, 146-151.	2.3	17
156	Effects of antisense mediated inhibition of cathepsin K on human osteoclasts obtained from peripheral blood. Journal of Orthopaedic Research, 2006, 24, 1699-1708.	1.2	10
157	Serum Levels of Osteoprotegerin and Receptor Activator of Nuclear Factor-ÎºB Ligand as Markers of Periprosthetic Osteolysis. Journal of Bone and Joint Surgery - Series A, 2006, 88, 1501-1509.	1.4	45
158	MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Research, 2006, 66, 4750-4757.	0.4	123
159	SERUM LEVELS OF OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-ÎºB LIGAND AS MARKERS OF PERIPROSTHETIC OSTEOLYSIS. Journal of Bone and Joint Surgery - Series A, 2006, 88, 1501-1509.	1.4	4
160	Primitive and bone metastatic renal carcinoma cells promote osteoclastogenesis through endothelial cells. Anticancer Research, 2006, 26, 3065-9.	0.5	2
161	Height as a Risk Factor for Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2005, 27, 314-318.	0.3	70
162	Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. Biomaterials, 2005, 26, 2371-2379.	5.7	75

#	Article	IF	Citations
163	The effect of irradiation modification and RGD sequence adsorption on the response of human osteoblasts to polycaprolactone. Biomaterials, 2005, 26, 4793-4804.	5.7	69
164	Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses. Monthly Notices of the Royal Astronomical Society: Letters, 2005, 76, 61-66.	1.2	6
165	In vitro blockade of receptor activator of nuclear factor-?B ligand prevents osteoclastogenesis induced by neuroblastoma cells. International Journal of Cancer, 2004, 111, 829-838.	2.3	45
166	Isolation and characterization of a new cell line from a renal carcinoma bone metastasis. Anticancer Research, 2004, 24, 1705-11.	0.5	5
167	Expression Profiling of Osteosarcoma Cells Transfected with MDR1 and NEO Genes: Regulation of Cell Adhesion, Apoptosis, and Tumor Suppression-Related Genes. Laboratory Investigation, 2003, 83, 507-517.	1.7	25
168	Plasma levels of coagulation inhibitors, fibrinolytic markers and platelet-derived growth factor-AB in patients with failed hip prosthesis. Acta Orthopaedica, 2003, 74, 559-564.	1.4	1
169	Immunological changes in patients with primary osteoarthritis of the hip after total joint replacement. Journal of Bone and Joint Surgery: British Volume, 2003, 85, 758-64.	3.4	20
170	Intracellular pH regulation in U-2 OS human osteosarcoma cells transfected with P-glycoprotein. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 125-138.	1.9	7
171	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Therapy, 2002, 9, 296-307.	2.2	101
172	Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene, 2002, 21, 1295-1298.	2.6	62
173	Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry, 2001, 46, 50-56.	1.8	41
174	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. International Journal of Cancer, 2000, 87, 328-335.	2.3	21
175	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	1.2	22
176	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	2.6	35
177	Redundancy of autocrine loops in human osteosarcoma cells. , 1999, 80, 581-588.		78
178	c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. , 1999, 84, 273-277.		48
179	Frequency and Implications of Chromosome 8 and 12 Gains in Ewing Sarcoma. Cancer Genetics and Cytogenetics, 1998, 100, 106-110.	1.0	75
180	Predictive Factors of Histological Response to Primary Chemotherapy in Ewing's Sarcoma. Acta OncolÃ³gica, 1998, 37, 671-676.	0.8	19

#	Article	IF	Citations
181	Retinoblastoma Susceptibility Gene Product Retrieval in Formalin-fixed, Paraffin-embedded Tissue: A Heating Method for Enhancing Immunohistochemical Staining.. Acta Histochemica Et Cytochemica, 1998, 31, 193-196.	0.8	1
182	Ki-67 Antigen Retrieval in Formalin- or Ethanol-fixed, Paraffin-embedded Tissues: An Enhancement Method for Immunohistochemical Staining with Autoclave Treatment.. Acta Histochemica Et Cytochemica, 1997, 30, 251-255.	0.8	4
183	Multidrug resistance â€" a multiplex phenomenon. Nature Medicine, 1997, 3, 378-380.	15.2	59
184	Increase of nuclear phosphatidylinositol 4,5-bisphosphate and phospholipase C Î²1 is not associated to variations of protein kinase C in multidrug-resistant Saos-2 cells. Microscopy Research and Technique, 1997, 36, 172-178.	1.2	11
185	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Human Pathology, 1996, 27, 408-416.	1.1	94
186	Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells. Histochemistry and Cell Biology, 1996, 106, 457-464.	0.8	33
187	Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology, 1996, 19, 253-256.	0.7	6
188	Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells. Histochemistry and Cell Biology, 1996, 106, 457-464.	0.8	2
189	Clinical relevance of Ki-67 expression in bone tumors. Cancer, 1995, 75, 806-814.	2.0	90
190	Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. New England Journal of Medicine, 1995, 333, 1380-1385.	13.9	372
191	Multidrug-resistance (MDR) phenotype of human osteosarcoma cells evaluated by quantitative morphological and electron microscopy analyses. Biology of the Cell, 1995, 84, 195-204.	0.7	5
192	Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. International Journal of Cancer, 1994, 58, 95-101.	2.3	15
193	Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. Journal of Cancer Research and Clinical Oncology, 1992, 119, 121-126.	1.2	13
194	Giant cell reparative granuloma and other giant cell lesions of the bones of the hands and feet. Skeletal Radiology, 1986, 15, 415-421.	1.2	59
195	Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor. Cancer, 1985, 56, 1515-1521.	2.0	260
196	Organisational Change and the Institutionalisation of University Patenting Activity in Italy. SSRN Electronic Journal, 0, , .	0.4	4
197	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1
198	Diffusion of Organisational Practices in Turbulent Environments: An Empirical Analysis of University-Level Patent Regulations. SSRN Electronic Journal, 0, , .	0.4	2